A critical evaluation of inflammatory markers in huntingtons disease plasma

Journal of Huntington's Disease

Volumn 2, Issue 1, 2013, Pages 125-134

  Silajdžić, Edina ^a   Rezeli, Melinda ^b   Végvári, Ákos ^b   Lahiri, Nayana ^c   Andre, Ralph ^c   Magnusson Lind, Anna ^a   Nambron, Rajasree ^c   Kalliolia, Eirini ^c   Marko Varga, György ^b   Warner, Thomas T ^c   Laurell, Thomas ^b   Tabrizi, Sarah J ^c   Björkqvist, Maria ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; C reactive protein; Complement; Huntingtons disease; Inflammation; Innate immunity

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; COMPLEMENT;

ADULT; AGED; ARTICLE; BLOOD; FEMALE; HUMAN; HUNTINGTON CHOREA; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; LIQUID CHROMATOGRAPHY; MALE; MIDDLE AGED; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

BIOMARKER; C-REACTIVE PROTEIN; COMPLEMENT; HUNTINGTON'S DISEASE; INFLAMMATION; INNATE IMMUNITY;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; HUNTINGTON DISEASE; INFLAMMATION; MALE; MIDDLE AGED; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84902531241     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-130049     Document Type: Article

References (43)

1. Bates GHP, Jones L, editors. Huntington’s Disease: Oxford University Press; 2002.
2. Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol. 2001;60(2): 161-72.
3. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Microglial activation in presymptomatic Huntington’s disease gene carriers. Brain. 2007;130(Pt 7): 1759-66.
4. Bjorkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, et al.Anovel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J Exp Med. 2008;205(8): 1869-77.
5. Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Bjorkqvist M, Petersen A, et al. Proteomic profiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res. 2007;6(7): 2833-40.
6. Suffredini AF, Fantuzzi G, Badolato R, Oppenheim JJ, O’Grady NP. New insights into the biology of the acute phase response. J Clin Immunol. 1999;19(4): 203-14.
7. Wild E, Magnusson A, Lahiri N, Krus U, Orth M, Tabrizi SJ, et al. Abnormal peripheral chemokine profile in Huntington’s disease. PLoS Curr. 2011;3: RRN1231.
8. CarrollMV, Sim RB. Complement in health and disease. Adv Drug Deliv Rev. 2011;63(12): 965-75.
9. Singhrao SK, Neal JW, Morgan BP, Gasque P. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington’s disease. Exp Neurol. 1999;159(2): 362-76.
10. Foell D, Frosch M, Sorg C, Roth J. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta. 2004;344(1-2): 37-51.
11. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(6): 524-34.
12. Perera C, McNeilHP, Geczy CL. S100 Calgranulins in inflammatory arthritis. Immunol Cell Biol. 2010;88(1): 41-9.
13. Burger D, Dayer JM. High-density lipoprotein-associated apolipoprotein A-I: The missing link between infection and chronic inflammation? Autoimmun Rev. 2002;1(1-2): 111-7.
14. Keene CD, Cudaback E, Li X, Montine KS, Montine TJ. Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer’s disease. Curr Opin Neurobiol. 2011;21(6): 920-8.
15. Lynch JR, Morgan D, Mance J, Matthew WD, Laskowitz DT. Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J Neuroimmunol. 2001;114(1-2): 107-13.
16. Ophir G, Amariglio N, Jacob-Hirsch J, Elkon R, Rechavi G, Michaelson DM. Apolipoprotein E4 enhances brain inflammation by modulation of the NF-kappaB signaling cascade. Neurobiol Dis. 2005;20(3): 709-18.
17. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev. 2005;208: 207-27.
18. Mundy GR. Osteoporosis and inflammation. Nutr Rev. 2007;65(12 Pt 2): S147-51.
19. Wild EJ, Tabrizi SJ. Predict-HD and the future of therapeutic trials. Lancet Neurol. 2006;5(9): 724-5.
20. Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, et al. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: The 12- month longitudinal analysis. Lancet Neurol. 2011;10(1): 31-42.
21. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9): 791-801.
22. Unified Huntington’s Disease Rating Scale: Reliability and consistency. Huntington Study Group. Mov Disord. 1996;11(2): 136-42.
23. Shoulson I, Fahn S. Huntington disease: Clinical care and evaluation. Neurology. 1979;29(1): 1-3.
24. Addona TA, Shi X, Keshishian H, Mani DR, Burgess M, Gillette MA, et al. A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat Biotechnol. 2011;29(7): 635-43.
25. Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: Workflows, potential, pitfalls and future directions. Nat Methods. 2012;9(6): 555-66.
26. Keshishian H, Addona T, Burgess M, Mani DR, Shi X, Kuhn E, et al. Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics. 2009;8(10): 2339-49.
27. Kuzyk MA, Smith D, Yang J, Cross TJ, Jackson AM, Hardie DB, et al. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics. 2009;8(8): 1860-77.
28. Soulet D, Cicchetti F. The role of immunity in Huntington’s disease. Mol Psychiatry. 2011;16(9): 889-902.
29. Collins LM, Toulouse A, Connor TJ, Nolan YM. Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology. 2012;62(7): 2154-68.
30. Holmes C, Cunningham C, Zotova E, Culliford D, Perry VH. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology. 2011;77(3): 212-8.
31. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009;73(10): 768-74.
32. Aiyaz M, LuptonMK, Proitsi P, Powell JF, Lovestone S. Complement activation as a biomarker for Alzheimer’s disease. Immunobiology. 2012;217(2): 204-15.
33. Bjorkqvist M, Ohlsson M, Minthon L, Hansson O. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer’s disease. PLoS One. 2012;7(1): e29868.
34. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, et al. Proteome-based plasma biomarkers for Alzheimer’s disease. Brain. 2006;129(Pt 11): 3042-50.
35. Cutler P, Akuffo EL, Bodnar WM, Briggs DM, Davis JB, Debouck CM, et al. Proteomic identification and early validation of complement 1 inhibitor and pigment epitheliumderived factor: Two novel biomarkers of Alzheimer’s disease in human plasma. Proteomics Clin Appl. 2008;2(4): 467-77.
36. Larkin PB, Muchowski PJ. Genetic Deficiency of Complement Component 3 Does Not Alter Disease Progression in a Mouse Model of Huntington’s Disease. J Huntingtons Dis. 2012;1(1): 107-18.
37. Chiang MC, Chern Y, Juo CG. The dysfunction of hepatic transcriptional factors in mice with Huntington’s Disease. Biochim Biophys Acta. 2011;1812(9): 1111-20.
38. Gibbons AS, Udawela M, Jeon WJ, Seo MS, Brooks L, Dean B. The neurobiology of APOE in schizophrenia and mood disorders. Front Biosci. 2011;16: 962-79.
39. Arnold SE, Xie SX, Leung YY, Wang LS, Kling MA, Han X, et al. Plasma biomarkers of depressive symptoms in older adults. Transl Psychiatry. 2012;2: e65.
40. Altindag O, Altindag A, Asoglu M, Gunes M, Soran N, Deveci Z. Relation of cortisol levels and bone mineral density among premenopausal women with major depression. Int J Clin Pract. 2007;61(3): 416-20.
41. Kahl KG, Greggersen W, Rudolf S, Stoeckelhuber BM, Bergmann-Koester CU, Dibbelt L, et al. Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. Psychosom Med. 2006;68(5): 669-74.
42. Kahl KG, Rudolf S, Dibbelt L, Stoeckelhuber BM, Gehl HB, Hohagen F, et al. Decreased osteoprotegerin and increased bone turnover in young female patients with major depressive disorder and a lifetime history of anorexia nervosa. Osteoporos Int. 2005;16(4): 424-9.
43. Michelson D, Stratakis C, Hill L, Reynolds J, Galliven E, Chrousos G, et al. Bone mineral density in women with depression. N Engl J Med. 1996;335(16): 1176-81.